PhenoVista Biosciences

Founded in 2014 and based in San Diego, PhenoVista Biosciences is a specialized CRO that has established itself as a trusted partner for biopharma companies in the preclinical space. The company's core expertise lies in designing and executing complex, high-content imaging-based assays using diverse cell models, including primary cells, iPSC-derived lines, and 3D co-cultures. With a strong client base that includes over 90% of top pharmaceutical companies and an 80% repeat customer rate, PhenoVista leverages its deep quantitative biology experience and advanced informatics to de-risk R&D decisions for its clients. Its service-only model focuses on generating high-quality, mechanistic data to accelerate early-stage drug discovery.

High-content imaging (HCI) and phenotypic screening platform utilizing multiplexed fluorescence assays, advanced cell models (2D, 3D, iPSC, primary), and machine learning/AI-driven image analysis to provide quantitative biological data for drug discovery.

Competes with other specialized preclinical CROs offering high-content screening (e.g., DiscoverX, part of Eurofins; certain offerings from Labcorp and Charles River), as well as internal capabilities at large pharmaceutical companies. Differentiation is based on deep expertise in complex assay development, a collaborative model, and a strong track record in specific therapeutic areas.